contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


publication-of-biohit-oyj-annual-report-2023

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Biohit is a medical technology company. The company develops and manufactures laboratory equipment, supplies, and diagnostic analysis systems adapted for research, care, and industrial laboratories. In addition to the main activities, technical support, maintenance, and training services are offered within the mentioned work area. The largest presence is in the Nordic market. The company is headquartered in Helsinki.

Här är en ny analys av Biohit.  Biohit issued a profit warning related to revenue, but despite this, the new 2024 earnings guidance (EBIT percentage 16-18%) clearly exceeded our expectations. Biohit’s profitability fluctuates, so we do not expect profitability to reach the very strong H2’24 level in the future. However, we raise our earnings forecasts moderately for the coming years based on the strong performance. The return/risk ratio of the stock that we already consider attractive improves another notch, so we raise our recommendation to Buy (was Accumulate) and raise the target price to EUR 2.9 (was 2.7).                   Inderes              Biohit: Performance surprised positively - Inderes    Biohit issued a profit warning related to revenue, but despite this, the new 2024 earnings guidance (EBIT percentage 16-18%) clearly exceeded our expectations.

Biohit sänkte sin omsättningsprognos för 2024, men samtidigt överträffade lönsamheten förväntningarna. Minskningen i omsättning beror på att leveranser har flyttats från slutet av året till 2025. Den nya prognosen (14,1–14,4 MEUR) är lägre än den tidigare, men rörelsemarginalen (16–18 %) har höjts, vilket tyder på ett starkt slut på året. Trots leveransförseningarna överträffar lönsamheten tidigare förväntningar. Utsikterna är fortfarande osäkra, men situationen klarnar i årsredovisningen.                    Inderes              Positive earnings surprise revealed under Biohit revenue guidance downgrade -...    Profitability has seen some ups and downs, so the sustainability of H2's excellent performance is still uncertain.

Nedan är en analytikers skrivelse om Biohits senaste uppdateringar.  Biohit that reports semi-annually does not publish business reviews for Q1 and Q3, but the company reports on its progress on the IR blog. The Q3 blog did not comment on progress against financial targets this time, so we expect the business to have continued to operate within the guidance range of 15-20% growth. The company said it is working on a major market launch that, if successful, could bring sales from mid-2025. The FDA approval project is also proceeding according to plan and the company is seeking a marketing authorization in the United States in 2026.                   Inderes              Biohit is working on a new market launch and FDA approval - Inderes    Biohit that reports semi-annually does not publish business reviews for Q1 and Q3, but the company reports on its progress on the IR blog. The Q3 blog did not comment on progress against financial targets this time, so we expect the business to...

Biohits framtidsutsikter splittrade - tillväxt men också osäkerhet  Biohits verksamhet har varierat under de senaste åren. Även om omsättningen har ökat måttligt har den länge varit förlustbringande. År 2022 vände rörelseresultatet till vinst, men detta berodde delvis på effektivisering av verksamheten och är inte nödvändigtvis en permanent trend. Bolagets produktportfölj är föråldrad och inga betydande nya produkter har lanserats på marknaden. Detta kan försämra Biohits konkurrenskraft i framtiden. Nya versioner av GastroPanel®-produktfamiljen är inte tillräckliga för att behålla konkurrensfördelen. Misslyckanden med utvecklingen av nya produkter kan äventyra bolagets långsiktiga framgång. Biohits strategi fokuserar på mag-tarmkanalens diagnostik. Konkurrenter har dock liknande lösningar, så bolagets framgång beror i hög grad på framgångsrika nya innovationer. Ur investerarens synvinkel är Biohits framtidsutsikter osäkra. Bolagets balansräkning är stark, men dess långsiktiga tillväxt och lönsamhet beror på framgångsrik produktutveckling. Den nya vd:n har haft en positiv inverkan, men stigande kostnader kan försämra lönsamheten. Begränsade resurser jämfört med konkurrenter ökar också riskerna. Biohits aktie är inte dyr, men den är förknippad med hög risk. Bolagets lilla storlek och osäkerheten om resultattrendens hållbarhet ökar riskerna för investerare. Tillväxten kan bli lägre än förväntat och stigande kostnader och osäkerheter kan ha en negativ inverkan på bolagets resultat. Ta inte alltför allvarligt på det, jag är bara en vanlig investerare.

I fredags meddelade Biohit att de kommer att förändra sin organisation för att stärka företagets strategiska och operativa prestation inom forskning och utveckling. Och här är en analytikers tankar om detta.                    Inderes              Biohit strengthens R&D - Inderes    On Friday, Biohit announced that it will change its organization to strengthen the company’s strategic and operational performance of R&D.

This article contains analyst comments regarding the first quarter.                    Inderes              Biohit's Q1 has gone according to plan - Inderes    Biohit that reports semi-annually does not publish business reviews for Q1 and Q3 but the company reports on its progress in the CEO’s blog. According to the blog, the implementation of the new strategy 2024-2028 started in Q1 as planned and on...

Säker avkastning och enorm tillväxt?  Här är en färsk analys av ett intressant företag.                   Inderes              Biohit: Growth measures taking effect - Inderes    Biohit’s H2 exceeded our expectations in terms of growth and earnings were in line with our forecasts. Revenue growth was supported by positive development in various products and markets.                             Biohit’s H2 exceeded our expectations in terms of growth and earnings were in line with our forecasts. Revenue growth was supported by positive development in various products and markets. We raise our revenue growth forecasts with the company’s good track record. We raise our earnings forecasts more moderately due to the increase in cost levels. The valuation picture has remained largely unchanged and the risk/reward ratio of the stock is attractive enough in our opinion to support a Buy recommendation.

Biohit

Biohit Oyj Annual Financial Report March 20, 2024 at 09:30 am local time (EET)Biohit Oyj’s Annual Report 2023 is published today in PDF and XHTML format. The annual report contains financial...

<p>Biohit Oyj Annual Financial Report March 20, 2024 at 09:30 am local time (EET)</p><p>Biohit Oyj’s Annual Report 2023 is published today in PDF and XHTML format. The annual report contains financial statements for 2023, the Report of the Board of Directors and Corporate Governance Statements. Information in ESEF format has not been audited. Annual report is published in Finnish and English, and it can be read and downloaded from Biohit company website:</p><p><a href="https://sijoittajat.biohithealthcare.com/en/investors/reports_and_presentations">Biohit (biohithealthcare.com)</a></p><p>&nbsp;</p><p>CEO&nbsp;Jussi Hahtela, Biohit Oyj</p><p>tel. +358 9 773&nbsp;861<br><a href="mailto:investor.relations@biohit.fi">investor.relations@biohit.fi</a><br><a href="https://www.biohithealthcare.com/en/">www.biohithealthcare.com</a></p><p>&nbsp;</p><p><em>Biohit in brief</em></p><p><em>Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.&nbsp;</em><a href="https://www.globenewswire.com/Tracker?data=c5rWyQltbzVNETEAzPUZ5WLkdGhFEQ1oTBo35iEHNX8xhFJ8UXxKcBfwNUj1oaJLkJWDIfhT0_qN_43uOPrHsIIWy25pE_7iX8aTY-nisGmlggNS87UH1ViJkQ-0ezca"><em>www.biohithealthcare.com</em></a></p>    <div>      <hr>      <div><strong>Attachments</strong></div>      <div><a href="https://storage.googleapis.com/inderes-widgets-prod-assets/biohit/attachments/55101513-a4e6-4415-a46e-65b7a21e92d9/74370089attsnbxjvt29-2023-12-31-en.zip">74370089ATTSNBXJVT29-2023-12-31-en.zip</a></div><div><a href="https://storage.googleapis.com/inderes-widgets-prod-assets/biohit/attachments/f0464705-cb58-49ea-9362-1494d5738051/biohit-oyj-annual-report-2023.pdf">Biohit Oyj Annual report 2023.pdf</a></div>    </div>

Stay up to date with our newsletter